All In Biotech

NDA 050805 · Galderma Labs Lp

Oracea

Doxycycline · Oral · Tetracycline-class Drug

Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

May 26, 2006

Approved uses

1

Original approval plus efficacy supplements

Registered trials

428

84 Phase 3, 42 recruiting

FAERS reports

52,695

40,506 serious, 4,857 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 16, 2025.

ORACEA is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ( 1. 1) Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. ( 1.2 ) ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. ( 1.2 ) 1.1 Indication ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. 1.2 Limitations of Use This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. Do not use ORACEA for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea.

Mechanism: The mechanism of action of ORACEA in the treatment of inflammatory lesions of rosacea is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORACEA · DOXYCYCLINE 40MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxycycline" as an intervention, any sponsor and status, largest first.

All 428 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,245
  • off label use3,726
  • nausea3,620
  • fatigue3,273
  • dyspnoea3,083
  • rash3,043
  • diarrhoea2,980
  • headache2,842
  • pain2,833
  • vomiting2,765
  • malaise2,319
  • condition aggravated2,182

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004221
2005315
2006322
2007353
2008425
2009693
2010943
20111,157
20121,296
20131,411
20141,669
20152,008
20162,598
20172,631
20183,286
20194,166
20203,994
20213,551
20223,933
20234,700
20244,938
20254,762
20263,323

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Oracea (Doxycycline Monohydrate)

2024 spending

$3.2M

Beneficiaries

750

2,605 claims

Per beneficiary

$4,325

$28.58 per unit

View as table
YearSpending
2020$3,949,239
2021$3,585,098
2022$3,437,037
2023$3,911,292
2024$3,243,701

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,510 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.